Screening for familial hypercholesterolaemia

Pathology

Volumn 44, Issue 2, 2012, Pages 122-128

  Bender, Robert ^a,b   Bell, Damon A ^a,b,c   Hooper, Amanda J ^a,b,d   Edwards, Glenn ^c   Van Bockxmeer, Frank M ^a,d   Watts, Gerald F ^a,b   Burnett, John R ^a,b,d  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c Osborne Park   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

ApoB; Cascade screening; Familial hypercholesterolaemia; Genetic testing; Index case; LDL cholesterol; LDL receptor

Indexed keywords

EID: 84858311039     PISSN: 00313025     EISSN: 14653931     Source Type: Journal    
DOI: 10.1097/PAT.0b013e32834efa07     Document Type: Article

References (78)

1. Austin MA, Hutter CM, Zimmern RL, Humphries SE. Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review. Am J Epidemiol 2004; 160: 407-20. (Pubitemid 39166973)
2. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003; 168: 1-14. (Pubitemid 36559596)
3. Rader DJ, Cohen J, Hobbs HH. Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 2003; 111: 1795-803. (Pubitemid 38057721)
4. Soutar AK, Naoumova RP. Mechanisms of disease: genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2007; 4: 214-25. (Pubitemid 46502094)
5. Bates TR, Burnett JR, van Bockxmeer FM, et al. Detection of familial hypercholesterolaemia: a major treatment gap in preventative cardiology. Heart Lung Circ 2008; 17: 411-3.
6. Hamilton-Craig I. Case-finding for familial hypercholesterolemia in the Asia-Pacific region. Semin Vasc Med 2004; 4: 87-92. (Pubitemid 38393295)
7. Muir LA, George PM, Laurie AD, et al. Preventing cardiovascular disease: a review of the effectiveness of identifying the people with familial hypercholesterolaemia in New Zealand. NZ Med J 2010; 123: 97-102.
8. Pijlman AH, Huijgen R, Verhagen SN, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional studyinThe Netherlands. Atherosclerosis 2010; 209: 189-94.
9. Müller C. Xanthomata, hypercholesterolemia, angina pectoris. Acta Med Scand 1938; 89: 75.
10. Khachadurian AK. The inheritance of essential familial hypercholestero-lemia. Am J Med 1964; 37: 402-7.
11. Goldstein JL, Hobbs HH, Brown MS. Familial hypercholesterolemia. In: Scriver CR, Beaudet AL, Sly WS, et al., editors. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York: McGraw-Hill, 2001; 2863-2913.
12. Liyanage KE, Burnett JR, Hooper AJ, van Bockxmeer FM. Familial hypercholesterolemia: epidemiology, Neolithic origins and modern geographic distribution. Crit Rev Clin Lab Sci 2011; 48: 1-18.
13. University College London. UCL LOVD LDLR Database. 2011 (cited October 2011). http://www.ucl.ac.uk/ldlr/LOVDv.1.1.0/
14. Soria LF, Ludwig EH, Clarke HR, et al. Association between a specific apolipoprotein B mutation and familial defective apolipoprotein B-100. Proc Natl Acad Sci USA 1989; 86: 587-91. (Pubitemid 19037786)
15. Lambert G. Unravelling the functional significance of PCSK9. Curr Opin Lipidol 2007; 18: 304-9. (Pubitemid 46743055)
16. Slack J. Risks of ischaemic heart-disease in familial hyperlipoproteinaemic states. Lancet 1969; 2: 1380-2.
17. Stone NJ, Levy RI, Fredrickson DS, Verter J. Coronary artery disease in 116 kindred with familial type II hyperlipoproteinemia. Circulation 1974; 49: 476-88.
18. Tonstad S, Joakimsen O, Stensland-Bugge E, et al. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arterioscler Thromb Vasc Biol 1996; 16: 984-91. (Pubitemid 26266897)
19. Wiegman A, de Groot E, Hutten BA, et al. Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet 2004; 363: 369-70. (Pubitemid 38169546)
20. Khachadurian AK, Uthman SM. Experiences with the homozygous cases of familial hypercholesterolemia. A report of 52 patients. Nutr Metab 1973; 15: 132-40.
21. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991; 303: 893-6.
22. World Health Organization (WHO). Familial Hypercholesterolemia. Report of a Second WHO Consultation. Geneva: WHO, 1999.
23. Williams RR, Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993; 72: 171-6. (Pubitemid 23205873)
24. Damgaard D, Larsen ML, Nissen PH, et al. The relationship of molecular genetic to clinical diagnosis of familial hypercholesterolemia in a Danish population. Atherosclerosis 2005; 180: 155-60.
25. Starr B, Hadfield SG, Hutten BA, et al. Development of sensitive and specific age- and gender-specific low-density lipoprotein cholesterol cutoffs for diagnosis of first-degree relatives with familial hyperchole-sterolaemia in cascade testing. Clin Chem Lab Med 2008; 46: 791-803. (Pubitemid 351821631)
26. Bates TR, Poulter EB, van Bockxmeer FM, Watts G. Family history: the neglected risk factor in disease prevention. Med J Aust 2010; 193: 429-30.
27. Emery JD, Walter FM, Ravine D. Family history: the neglected risk factor in disease prevention. Med J Aust 2010; 192: 677-8.
28. Watts GF, Sullivan DR, Poplawski N, et al. Familial hypercholesterolae- mia: a model of care for Australasia. Atheroscler Suppl 2011; 12: 221-63.
29. Leigh SE, Foster AH, Whittall RA, et al. Update and analysis of the University College London low density lipoprotein receptor familial hy-percholesterolemia database. Ann Hum Genet 2008; 72: 485-98. (Pubitemid 351850090)
30. Bodamer OA, Bercovich D, Schlabach M, et al. Use of denaturing HPLC to provide efficient detection of mutations causing familial hypercholestero-lemia. Clin Chem 2002; 48: 1913-8. (Pubitemid 35222748)
31. Bunn CF, Lintott CJ, Scott RS, George PM. Comparison of SSCP and DHPLC for the detection of LDLR mutations in a New Zealand cohort. Hum Mutat 2002; 19: 311.
32. Laurie AD, George PM. Evaluation of high-resolution melting analysis for screening the LDL receptor gene. Clin Biochem 2009; 42: 528-35.
33. Whittall RA, Scartezini M, Li K, et al. Development of a high-resolution melting method for mutation detection in familial hypercholesterolaemia patients. Ann Clin Biochem 2010; 47: 44-55.
34. Bourbon M, Duarte MA, Alves AC, et al. Genetic diagnosis of familial hypercholesterolaemia: the importance of functional analysis of potential splice-site mutations. J Med Genet 2009; 46: 352-7.
35. Wright WT, Heggarty SV, Young IS, et al. Multiplex MassARRAY spectro-metry (iPLEX) produces a fast and economical test for 56 familial hypercholesterolaemia-causing mutations. Clin Genet 2008; 74: 463-8.
36. Taylor A, Wang D, Patel K, et al. Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project. Clin Genet 2010; 77: 572-80.
37. Alonso R, Defesche JC, Tejedor D, et al. Genetic diagnosis of familial hypercholesterolemia using a DNA-array based platform. Clin Biochem 2009; 42: 899-903.
38. Chiou KR, Charng MJ, Chang HM. Array-based resequencing for mutations causing familial hypercholesterolemia. Atherosclerosis 2011; 216: 383-9.
39. Duskova L, Kopeckova L, Jansova E, et al. An APEX-based genotyping microarray for the screening of 168 mutations associated with familial hypercholesterolemia. Atherosclerosis 2011; 216: 139-45.
40. Watts GF, Dimmitt S, Redgrave T, et al. Model of Care: Familial Hypercholesterolaemia. Perth: Office of Population Health Genomics, 2008. http://www.genomics.health.wa.gov.au/fh/docs/FH-Model-of-care. pdf
41. Burnett JR, Ravine D, van Bockxmeer FM, Watts GF. Familial hypercho-lesterolaemia: a look back, a look ahead. Med J Aust 2005; 182: 552-3 (Pubitemid 40823469)
42. Sullivan D. Guidelines for the diagnosis and management of familial hypercholesterolaemia. Heart Lung Circ 2007; 16: 25-7. (Pubitemid 46140718)
43. Tonkin A, Barter P, Best J, et al. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Position Statement on Lipid Management-2005. Heart Lung Circ 2005; 14: 275-91.
44. Watts GF, van Bockxmeer FM, Bates T, et al. A new model of care for familial hypercholesterolaemia from Western Australia: closing a major gap in preventive cardiology. Heart Lung Circ 2010; 19: 419-22.
45. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376: 1670-81.
46. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-78.
47. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009; 338: b2376.
48. de Jongh S, Lilien MR, op't Roodt J, et al. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol 2002; 40: 2117-21. (Pubitemid 36005896)
49. Harada-Shiba M, Sugisawa T, Makino H, et al. Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia. J Atheroscler Thromb 2010; 17: 667-74.
50. Ito MK, McGowan MP, Moriarty PM. Management of familial hyper-cholesterolemias in adult patients: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5: S38-45.
51. Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J 2008; 29: 2625-33.
52. Robinson JG, Goldberg AC. Treatment of adults with familial hyper-cholesterolemia and evidence for treatment: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterole-mia. J Clin Lipidol 2011; 5: S18-29.
53. Smilde TJ, van Wissen S, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357: 577-81. (Pubitemid 32179609)
54. Versmissen J, Oosterveer DM, Yazdanpanah M, et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008; 337: a2423.
55. Ward S, Lloyd Jones M, Pandor A, et al. A systematic review and economic evaluation of statins for the prevention of coronary events. Health Technol Assess 2007; 11: 1-160; iii-iv.
56. Alonso R, Fernandez de Bobadilla J, Mendez I, et al. Cost-effectiveness of managing familial hypercholesterolemia using atorvastatin-based preventive therapy. (Spanish.) Rev Esp Cardiol 2008; 61: 382-93. (Pubitemid 351838467)
57. Nherera L, Calvert NW, Demott K, et al. Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia. Curr Med Res Opin 2010; 26: 529-36.
58. Hamilton-Craig I, Kostner K, Colquhoun D, Woodhouse S. Combination therapy of statin and ezetimibe for the treatment of familial hypercholes-terolemia. Vasc Health Risk Manag 2010; 6: 1023-37.
59. Toth PP. Drug treatment of hyperlipidaemia: a guide to the rational use of lipid-lowering drugs. Drugs 2010; 70: 1363-79.
60. Wilson JM, Jungner G. Principles and Practice of Screening for Disease. Geneva: World Health Organization, 1968.
61. Tyerman PF, Tyerman GV. Another way of screening for familial hypercholesterolaemia. BMJ 2002; 325: 340.
62. Gray J, Jaiyeola A, Whiting M, et al. Identifying patients with familial hypercholesterolaemia in primary care: an informatics-based approach in one primary care centre. Heart 2008; 94: 754-8. (Pubitemid 351744695)
63. Datta BN, McDowell IF, Rees A. Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemia. Curr Opin Lipidol 2010; 21: 366-71.
64. Minhas R, Humphries SE, Qureshi N, Neil HA. Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia. Heart 2009; 95: 584-7; discussion 7-91.
65. Wald DS, Bestwick JP, Wald NJ. Child-parent screening for familial hypercholesterolaemia: screening strategy based on a meta-analysis. BMJ 2007; 335: 599.
66. Ritchie SK, Murphy EC, Ice C, et al. Universal versus targeted blood cholesterol screening among youth: The CARDIAC project. Pediatrics 2010; 126: 260-5.
67. Marks D, Wonderling D, Thorogood M, et al. Screening for hyper-cholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis. Health Technol Assess 2000; 4: 1-123.
68. Ned RM, Sijbrands EJ. Cascade screening for familial hypercholesterole- mia (FH). PLoS Curr 2011; 3: RRN1238.
69. Leren TP, Finborud TH, Manshaus TE, et al. Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. Community Genet 2008; 11: 26-35.
70. Umans-Eckenhausen MA, Defesche JC, van Dam MJ, Kastelein JJ. Longterm compliance with lipid-lowering medication after genetic screening for familial hypercholesterolemia. Arch Intern Med 2003; 163: 65-8. (Pubitemid 36091602)
71. Austin MA, Zimmern RL, Humphries SE. High 'population attributable fraction' for coronary heart disease mortality among relatives in monogenic familial hypercholesterolemia. Genet Med 2002; 4: 275-8. (Pubitemid 44698561)
72. Calonge N, Guirguis-Blake J. Screening for familial hypercholesterolae- mia. BMJ 2007; 335: 573-4.
73. Haney EM, Huffman LH, Bougatsos C, et al. Screening and treatment for lipid disorders in children and adolescents: systematic evidence review for the US Preventive Services Task Force. Pediatrics 2007; 120: e189-214. (Pubitemid 47036251)
74. Nherera L, Marks D, Minhas R, et al. Probabilistic cost-effectiveness analysis of cascade screening for familial hypercholesterolaemia using alternative diagnostic and identification strategies. Heart 2011; 97: 1175-81.
75. Wonderling D, Umans-Eckenhausen MA, Marks D, et al. Cost-effectiveness analysis of the genetic screening program for familial hypercholesterolemia in The Netherlands. Semin Vasc Med 2004; 4: 97-104. (Pubitemid 38393297)
76. Daniels SR, Gidding SS, de Ferranti SD. Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol 2011; 5: S30-7.
77. National Institute for Health and Clinical Excellence (NICE), The National Collaborating Centre for Primary Care. NICE Clinical Guideline 71: Identification and Management of Familial Hypercholesterolaemia. London: NICE, 2008. http://www.nice.org.uk/nicemedia/pdf/CG071NICE-Guideline.pdf.
78. Qureshi N, Humphries SE, Seed M, et al. Identification and management of familial hypercholesterolaemia: what does it mean to primary care? Br J Gen Pract 2009; 59: 773-6